2024년에 43억 달러로 추정되는 유전자 전달 시스템 세계 시장은 2024년부터 2030년까지 CAGR 6.5%로 성장하여 2030년에는 62억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 바이러스 유전자는 CAGR 6.9%를 기록하며 분석 기간 종료시에는 41억 달러에 달할 것으로 예측됩니다. 비바이러스 유전자 부문의 성장률은 분석 기간 동안 CAGR 6.2%로 추정됩니다.
미국 시장은 12억 달러로 추정, 중국은 CAGR 6.0%로 성장할 것으로 예측
미국의 유전자 전달 시스템 시장은 2024년에 12억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 9억 6,740만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 5.8%와 5.5%로 예측됩니다. 유럽에서는 독일이 CAGR 4.9%로 성장할 것으로 예측됩니다.
세계의 유전자 전달 시스템 시장 - 주요 동향과 촉진요인 정리
유전자 전달 시스템이란 무엇이며, 왜 현대 의료에 필수적인가?
유전자 전달 시스템은 생명공학 및 의학 분야에서 필수적인 도구로, 다양한 질병을 분자 수준에서 치료하기 위해 세포에 유전 물질을 도입할 수 있게 해줍니다. 이러한 시스템은 유전자 치료, 재생의료, 백신 개발에서 중요한 역할을 하고 있으며, 암, 유전질환, 감염성 질환 등의 질병에 대응하고 있습니다. 바이러스 벡터, 리포솜, 나노입자는 유전자 전달 시스템에서 가장 일반적으로 사용되는 방법 중 하나이며, 각기 다른 용도에 고유한 이점을 제공합니다. 맞춤형 의료 분야가 확대되면서 개별 환자의 요구에 맞는 정확한 유전자 개입을 가능하게 하는 이러한 시스템의 중요성이 더욱 강조되고 있습니다.
기술 혁신은 어떻게 유전자 전달을 진행하고 있는가?
CRISPR 기반 접근법이나 전기포식 등 비바이러스성 전달 방법의 혁신은 유전자 치료의 안전성과 효능을 향상시키고 있으며, 유전자 도입의 기술 발전은 이러한 시스템의 능력과 효율성에 혁명을 가져오고 있습니다. 또한, 면역계 활성화 및 제한된 표적화 능력과 같은 기존의 한계를 극복할 수 있는 합성 벡터의 개발로 유전자 도입의 응용 가능성이 확대되고 있습니다. 나노입자 공학의 발전은 유전자 물질을 보다 정확하게 전달하고, 제어된 상태로 방출할 수 있게 하여, 표적 외 영향을 줄이고, 환자의 결과를 개선하고 있습니다. 이러한 발전은 유전자 전달 시스템을 더 안전하고, 더 효과적이며, 더 광범위한 의료 응용 분야에 적합하게 만들었습니다.
유전자 치료 솔루션에 대한 수요가 증가하는 이유는 무엇인가?
유전자 치료 솔루션에 대한 수요는 만성질환 및 생명을 위협하는 질병에 대한 영구적인 치료법을 제공할 수 있다는 점에서 급증하고 있습니다. 유전학 및 분자생물학 연구가 발전함에 따라 유전자 치료로 치료할 수 있는 질환이 증가하고 있으며, 과거 불치병으로 여겨졌던 질환에 대한 새로운 치료법이 등장하고 있습니다. 희귀 유전성 질환, 암, 특정 감염성 질환은 유전자 치료의 주요 타겟이며, 효과적인 유전자 전달 시스템이 성공에 필수적입니다. 또한, 맞춤형 의료의 부상으로 인해 특정 표적 유전자 변형을 가능하게 하는 전달 시스템이 추진되고 있으며, 이는 개별 유전자 프로파일에 맞는 치료법을 만들어내는 헬스케어 업계의 목표에 부합하고 있습니다.
유전자 전달 시스템 시장의 성장 원동력은?
유전자 전달 시스템 시장의 성장은 생명공학의 발전, 유전자 치료에 대한 수요 증가, 맞춤형 의료에 대한 관심 증가 등 여러 요인에 의해 이루어지고 있으며, CRISPR 및 합성 벡터 개발과 같은 기술 발전은 보다 효율적이고 표적화된 유전자 도입 방법을 가능하게 하고, 치료 가능한 질병의 범위를 넓히고 있습니다. 치료 가능한 질환의 범위가 넓어지고 있습니다. 유전자 치료 솔루션이 유전성 질환과 암에 대한 잠재적 치료법으로 지지받으면서 효과적인 전달 시스템의 필요성이 증가하고 있습니다. 또한, 정밀의료에 대한 관심이 높아지면서 환자 개개인에 맞는 맞춤형 유전자 개입을 가능하게 하는 시스템이 요구되고 있습니다. 이러한 요인들이 결합하여 유전자 전달 시스템 시장은 현대 의학의 초석이 되고 있습니다.
부문
딜리버리(바이러스 유전자, 비바이러스 유전자, 복합 하이브리드), 용도(종양학, 중추신경계, 감염증, 안과, 당뇨병, 기타 용도)
조사 대상 기업 사례
Amgen, Inc.
Bayer AG
Human Stem Cells Institute
Johnson & Johnson
Novartis AG
Oxford Biomedica plc
Pfizer, Inc.
Shanghai Sunway Biotech Co., Ltd.
Sibiono GeneTech Co. Ltd.
AI 통합
Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
ksm
영문 목차
영문목차
Global Gene Delivery Systems Market to Reach US$6.2 Billion by 2030
The global market for Gene Delivery Systems estimated at US$4.3 Billion in the year 2024, is expected to reach US$6.2 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Viral Gene, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Non-Viral Gene segment is estimated at 6.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 6.0% CAGR
The Gene Delivery Systems market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$967.4 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Global Gene Delivery Systems Market - Key Trends & Drivers Summarized
What Are Gene Delivery Systems and Why Are They Essential in Modern Medicine?
Gene delivery systems are vital tools in the field of biotechnology and medicine, enabling the introduction of genetic material into cells to treat various diseases at a molecular level. These systems play a crucial role in gene therapy, regenerative medicine, and vaccine development, addressing conditions like cancer, genetic disorders, and infectious diseases. Viral vectors, liposomes, and nanoparticles are among the most commonly used methods in gene delivery systems, each offering unique benefits for different applications. The growing field of personalized medicine further underscores the importance of these systems, as they enable precise genetic interventions tailored to individual patients’ needs.
How Is Technological Innovation Advancing Gene Delivery?
Technological advancements in gene delivery are revolutionizing the capabilities and efficiency of these systems. Innovations in non-viral delivery methods, such as CRISPR-based approaches and electroporation, are increasing the safety and efficacy of gene therapies. Additionally, the development of synthetic vectors that can overcome traditional limitations, such as immune system activation and limited targeting capabilities, is expanding the potential applications of gene delivery. Advances in nanoparticle engineering allow for more precise delivery and controlled release of genetic material, reducing off-target effects and improving patient outcomes. These advancements are making gene delivery systems safer, more effective, and suitable for a broader range of medical applications.
Why Is There Growing Demand for Gene Therapy Solutions?
The demand for gene therapy solutions is surging due to their potential to offer lasting cures for chronic and life-threatening conditions. As research in genetics and molecular biology progresses, more diseases are becoming treatable through gene therapy, opening new avenues for conditions previously considered incurable. Rare genetic disorders, cancers, and certain infectious diseases are prime targets for gene therapy, where effective gene delivery systems are essential to success. Additionally, with the rise in personalized medicine, there is a push for delivery systems that allow specific, targeted genetic modifications, aligning with the healthcare industry’s goal of creating treatments tailored to individual genetic profiles.
What Drives the Growth of the Gene Delivery Systems Market?
The growth in the gene delivery systems market is driven by several factors, including advancements in biotechnology, increasing demand for gene therapies, and the rising focus on personalized medicine. Technological progress, such as CRISPR and synthetic vector development, has enabled more efficient and targeted gene delivery methods, expanding the range of treatable diseases. The need for effective delivery systems is growing as gene therapy solutions gain traction as potential cures for genetic disorders and cancers. Furthermore, the emphasis on precision medicine is pushing for systems that allow for specific, controlled genetic interventions tailored to individual patients. Collectively, these factors are propelling the gene delivery systems market forward as it becomes a cornerstone in modern medicine.
SCOPE OF STUDY:
The report analyzes the Gene Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 46 Featured) -
Amgen, Inc.
Bayer AG
Human Stem Cells Institute
Johnson & Johnson
Novartis AG
Oxford Biomedica plc
Pfizer, Inc.
Shanghai Sunway Biotech Co., Ltd.
Sibiono GeneTech Co. Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Tariff Impact on Global Supply Chain Patterns
Gene Delivery Systems - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Gene Therapy in Treating Genetic Disorders
Advancements in Viral and Non-Viral Gene Delivery Technologies
Increased Focus on Targeted and Precision Medicine for Enhanced Therapeutic Efficacy
Expansion of Gene Delivery Applications in Oncology and Rare Diseases
Growing Adoption of CRISPR and Other Gene Editing Tools for Gene Therapy
Surge in Research Funding for Developing Novel Gene Delivery Methods
Increased Demand for Safer and More Efficient Gene Delivery Vehicles
Development of Nanoparticle-Based Gene Delivery Systems for Better Bioavailability
Rising Investment in Gene Delivery for Regenerative Medicine and Cell Therapy
Expansion of Clinical Trials Investigating Gene Delivery for Neurological Disorders
Growth in Partnerships Between Biotech Firms and Academic Institutions
Focus on Improving Patient Outcomes and Reducing Side Effects in Gene Therapy
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Gene Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Non-Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Combined Hybrid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Canada 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
JAPAN
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 44: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Japan 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 47: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Japan 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
CHINA
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 50: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: China 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 53: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: China Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: China 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
EUROPE
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 56: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
FRANCE
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 65: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: France Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: France 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 68: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: France Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: France 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
GERMANY
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 71: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Germany 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 74: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Germany Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Germany 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
ITALY
TABLE 77: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Italy 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 80: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Italy Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Italy 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
UNITED KINGDOM
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 83: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: UK Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: UK 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 86: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: UK Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: UK 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
REST OF WORLD
TABLE 101: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Rest of World Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Rest of World 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
TABLE 104: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Rest of World Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Rest of World 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
